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Abstract 
Purpose of review 
The treatment of the germinal center (GC) lymphomas, diffuse large B-cell (DLBCL) 
and follicular lymphoma (FL), has changed little beyond the introduction of immuno-
chemotherapies. However, there exists a substantial group of patients within both 
diseases, for which improvements in care will involve appropriate tailoring of 
treatment. 
Recent findings 
DLBCL consists of two major subtypes with striking differences in their clinical 
outcomes paralleling their underlying genetic heterogeneity. Recent studies have 
seen advances in the stratification of GC lymphomas, through comprehensive 
profiling of 1001 DLBCLs alongside refinements in the identification of high-risk FL 
patients using m7-FLIPI and 23G models. A new wave of novel therapeutic agents is 
now undergoing clinical trials for GC lymphomas, with BCR and EZH2 inhibitors 
demonstrating preferential benefit in subgroups of patients. The emergence of cell-
free DNA has raised the possibility of dynamic disease monitoring to potentially 
mitigate the complexity of spatial and temporal heterogeneity, whilst predicting 
tumor evolution in real-time. 
Summary 
Altogether knowledge of the genomic landscape of GC lymphomas is offering 
welcome opportunities in patient risk stratification and therapeutics. The challenge 
ahead is to establish how best to combine upfront or dynamic prognostication with 









The treatment of the two most common forms of germinal center (GC) non-Hodgkin 
lymphomas (NHL), diffuse large B-cell (DLBCL) and Follicular lymphoma (FL), was 
revolutionized by the addition of rituximab to chemotherapeutic regimens (R-CHOP). 
Over half of DLBCL patients are now curable by R-CHOP, whilst despite FL being 
considered an incurable disease, the majority of FL patients live for upwards of 15 
years. Beyond these successes, prognosis remains poor for a third of relapsed-
refractory DLBCL patients, and for a quarter of FL patients who are prone to early 
relapse and/or transformation to a more aggressive lymphoma (tFL). There is 
renewed optimism that the molecular characterization of these diseases will allow 
for the prediction of high-risk patients and the tailoring of treatments based on a 
patient’s molecular profile. In this review, we will focus on the prognostic strategies 
to identify high-risk patients and the progress now being made in developing 
targeted therapies for these GC lymphomas. 
 
The molecular landscape of GC lymphomas.  
The introduction of next generation sequencing (NGS) sparked a dramatic increase in 
our understanding of the molecular events that drive GC lymphomas. There are now 
well over 200 recurring gene mutations described, although only a minority occur in 
greater than 5-10% of patients. The significance of gene translocations targeting 
MYC, BCL2, and BCL6 are all well established, as is the recognition of widespread 
disruption of the epigenome, predominantly driven by somatic mutations within 
KMT2D, CREBBP, EZH2 and linker histones [1-13]. DLBCL displays a greater degree of 
genetic heterogeneity than FL, and can be readily divided into at least two major 
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subtypes based on the “cell of origin” (COO): GC B cell (GCB)-like and activated B cell 
(ABC)-like DLBCL [14,15]. The ABC-DLBCL subtype has the poorer prognosis by far 
(40% 3-year overall survival (OS)) and is typified by constitutive NF-κB activation and 
signaling driven by somatic mutations in the B cell receptor (BCR) and NF-κB 
pathway genes (CARD11, CD79B, MYD88, and TNFAIP3) [16-20], whereas GCB-DLBCL 
has a better prognosis (80% 3-year OS) and more closely resembles FL. While there 
are specific gene mutations that are enriched in each group, the overall landscape is 
complex and contrary to earlier expectations, BCR and NF-κB pathways mutations 
also arise in GCB-DLBCL and FL, albeit at a lower frequency [2,11].  
 
Identifying high-risk DLBCL patients 
Overall, progress has been sluggish in discriminating high- from low-risk patients 
within the distinct COO entities with the exception of the “high-grade B cell 
lymphomas, with MYC and BCL2 and/or BCL6 rearrangements”, also known as 
double- and triple-hit lymphomas, and the “double-expressors” that highly express 
both BCL2 and MYC in the absence of rearrangements [21,22]. Both groups 
demonstrate an aggressive phenotype associated with poor outcomes and therefore 
are a high priority for clinical intervention. Nevertheless, we are likely to see an 
acceleration in improved prognostic models and refined patient subsets in the 
foreseeable future, as our understanding of the landscape of coding aberrations in 
DLBCL nears completion. A monumental study by Reddy and colleagues has set the 
pace with an extensive analysis of 1001 newly diagnosed DLBCL patients, integrating 
mutational profiling, gene expression analysis and clinical information, which has 
offered novel insights into combinatorial factors influencing outcome for near 
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enough the first time. While many of these observations will require validation, (for 
example KLH14 mutations being predictive of high-risk ABC-DLBCL, and EZH2 
mutations predicting low-risk GCB-DLBCL), the size and depth of the data allowed 
the authors to devise an encouraging prognostic multivariate genomic risk model 
[11]. Such large collaborative studies will undoubtedly be the benchmark for future 
studies and provides a framework for developing prospective risk-adapted strategies 
for DLBCL. 
 
A new era in FL stratification? 
Molecular stratification of FL has lagged behind DLBCL, with the COO classification 
first described nearly 20 years ago [14]. Traditional attempts at risk stratification in 
the era of immunochemotherapy have been based on clinical parameters such as 
the Follicular Lymphoma International Prognostic Index (FLIPI) scores, the FLIPI and 
FLIPI-2, but are for the most part fairly ineffective tools for directing management 
decisions [23,24]. While molecular prognostication has long been opined as having 
more potential, it is only of late that we are seeing inroads into the development of 
tools capable of navigating the clinical heterogeneity within FL and able to predict 
high-risk patients. The earliest studies by the Lymphoma/Leukemia Molecular 
Profiling Project stratified FL based on the patterns of two gene signatures 
associated with T cell and myeloid cell infiltration [25]. However, we may well have 
turned the corner with the recent development of the m7-FLIPI, a clinico-genetic risk 
model that incorporates the clinical features of the FLIPI and the mutational status 
of 7 genes (EP300, FOXO1 CREBBP, CARD11, MEF2B, ARID1A, EZH2) [26], and an 
alternative prognostic strategy based on the expression of 23 genes (23G model) 
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from both the tumor and microenvironment [27]. It is likely that these models will 
continue to evolve as they are impacted by treatment changes, such as the move 
towards   chemotherapy-free interventions, and we need to lay the groundwork for 
these changes by developing the infrastructure to enable head-to-head comparisons 
and reach a consensus on the level of discrimination needed to guide treatment, 
especially for an indolent disease such as FL where a high prognostic accuracy is 
necessary.  
 
Upfront prognostication verses dynamic disease monitoring  
All of the aforementioned clinical and molecular prognostic strategies are based on 
upfront testing and prognostication. However, sampling of a single site at diagnosis 
fails to account for the temporal [1,28-31] and spatial heterogeneity [32] observed in 
GC lymphomas. The assessment of cell-free DNA (cfDNA) from plasma samples 
offers the possibility of more effectively sampling the heterogeneity in GC 
lymphomas, and dynamically monitoring changes in prognostic markers and 
actionable targets in a minimally invasive manner. Whilst it has not been widely 
applied so far, early studies have suggested a number of possible applications 
including the ability to classify the COO in DLBCL patients and to predict 
transformation of FL [33-35]. In an era where there is a headlong shift away from 
excision biopsies, it is likely that non-invasive cfDNA-based diagnostics and 
prognostics will have a significant future role within GC lymphomas.  
 
Ibrutinib preferentially benefits ABC-DLBCL patients 
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Running in tandem with efforts at exploiting genetic data for defining risk, access to 
genetic profiles are also pointing the way towards novel therapies. Ibrutinib, which 
inhibits the BTK enzyme responsible for propagating pro-survival signals from the 
BCR, which is constitutively active in ABC-DLBCLs (Figure 1) [36], has proved to be 
revolutionary in the treatment of chronic lymphocytic leukemia [37], and 
accumulating data suggest that it may be efficacious in poor-risk, BCR/NF-κB-
dependent ABC-DLBCL patients. In a Phase I/II trial of 80 patients, single agent 
ibrutinib was well tolerated and had an overall response rate (ORR) of 37% in ABC-
DLBCL, compared to only 5% in GCB-DLBCL patients [36], and it is encouraging that 
all non-GCB patients achieved complete remission in a Phase I study examining 
ibrutinib in combination with rituximab-based chemotherapy [38]. Following the 
success of these trials, ibrutinib is being tested in several phase III trials for ABC-
DLBCL, that includes combination with R-CHOP for newly diagnosed ABC-DLBCL 
patients (NCT01855750), and in relapsed/refractory ABC-DLBCL patients undergoing 
stem cell transplant NCT02443077).  
 
In FL, single agent ibrutinib was shown to only have modest activity [39], despite 
evidence that BCR signaling has a role in FL pathogenesis [40-44]. Combination 
studies with rituximab have improved on the single-agent outcomes [45] but it 
seems sensible that upfront selection should be a feature of future trials, with 
evidence that MYD88 mutations are associated with a positive outcome in DLBCL 
[36], while CARD11 mutations appear to influence ibrutinib resistance in FL [39].  
 
EZH2 inhibitors may selectively benefit EZH2-mutant patients 
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The recent recognition of gain-of-function mutations in EZH2 demonstrates the 
speed by which discoveries relating to the molecular pathogenesis of a disease are 
translatable into potential clinical benefit. EZH2 is a histone methyltransferase that 
acts as the catalytic subunit of the polycomb repressor complex 2 and catalyzes 
repressive mono-, di- and tri-methylation of the histone 3 lysine 27 (H3K27) residue. 
In GC lymphomas, its important role in regulating the normal GC reaction [46] is 
subverted by heterozygous mutations most commonly altering tyrosine 646 (Y646) 
within the catalytic SET domain [47]. These gain-of-function mutations alter the 
catalytic activity of the mutant EZH2 enzyme so that it preferentially catalyzes the 
conversion of H3K27me1 into the strongly repressive H3K27me2/3 marks, whilst the 
wild-type protein continues to deposit H3K27me1 [48].  
 
Selective EZH2 inhibitors have been developed by Epizyme (EPZ6438, tazemetostat 
[49]), GlaxoSmithKline (GSK126 [50]) and Constellation Pharmaceuticals (CPI-1205 
[51]), with pre-clinical data indicating that these compounds are generally more 
active in mutant cell lines and able to re-activate genes repressed or silenced by 
mutant EZH2 [49-51]. Phase I/II clinical trials have now been launched for all of these 
compounds to examine their efficacy for NHL with recent interim data suggesting 
that tazemetostat is efficacious for EZH2-mutated FL patients (92% ORR in mutant vs 
26% in wild-type) and to a lesser extent in DLBCL (29% ORR in mutant vs 15% in wild-
type) [52]. Altogether, these results are encouraging and highlight the attractions of 
precision medicine although given that EZH2 mutations have been provisionally 
linked with better outcomes in GC lymphomas [26,53], EZH2 inhibitors will need to 
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demonstrate significant benefit over the current standard of care to justify their use 
as a targeted therapy in this sub-group of patients. 
 
Revisiting mTOR inhibitors in the light of recent developments   
It is also possible that armed with new insights into the genetic basis of GC 
lymphomas, we can revisit historical clinical studies and explore opportunities for 
precision treatments. Inhibition of the mTOR (mammalian Target Of Rapamycin) 
pathway, previously evaluated in FL, serves as a notable example with two phase II 
trials of second generation mTOR inhibitors, temsirolimus and everolimus, 
demonstrating promising results in multiply relapsed cohorts (ORR 53.8% [54] and 
ORR 38% [55], respectively). These trials however were performed before the 
discovery of unique mutations of the RRAGC and the V-ATPase ATP6V1B2 and 
ATP6AP1 genes in around 30% of FL patients, enforcing mTORC1 activation 
[4,,56,57]. With the spectrum of different molecular lesions that we are now aware 
of in GC lymphomas, there may be opportunities to re-examine previously trialed 
agents, to determine whether events such as mTOR pathway mutations are 
predictive of response. Equally this also reaffirms the need and value of rigorously 
collecting biopsy material as part of clinical trials for later correlative studies. 
 
New strategies to reverse the early loss of CREBBP in precursor cells 
Given the frequency and recognition of CREBBP mutations as one of the earliest 
events in GC lymphomas [8-11, 58-60], and their widespread role in promoting GC-
lymphoma development [4,58-62], the successful targeting of these lesions would 
offer an exciting new therapy with the potential to eradicate disease-propagating 
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cells. Indeed, phylogenetic analysis has revealed that overt FL, and subsequent 
relapses of the disease, are likely to develop from long-lived pre-malignant cells 
known as common progenitor cells (CPCs), which are believed to be t(14;18)-positive 
and typically contain mutations within the histone regulatory genes CREBBP and 
KMT2D [1,3-5,63-66]. There is a persuasive argument to suppose that inhibition of 
the histone deacetylase (HDAC) enzymes that normally oppose CREBBP by removing 
acetylation marks could mitigate the deep-rooted loss of histone acetyltransferases 
CREBBP and EP300. Overall, whilst pan-HDAC inhibitors have demonstrated efficacy 
in GC lymphomas [67-69], the occurrence of significant toxicities, alongside the 
absence of a biomarker and an unclear mechanism of action, have limited progress 
beyond phase II trials. Their fortunes may well change in the future, with recent 
studies exploring the relationship between CREBBP mutations and HDAC isoforms 
indicating that HDAC3 opposes the activity of CREBBP at enhancers and hyper-
represses these enhancers following the loss of CREBBP, resulting in an increased 
dependency on HDAC3 for survival [58]. Targeting the HDAC3 isoform thus offers a 
potential therapeutic strategy with the promise of re-activating CREBBP-regulated 
genes whilst minimizing toxicity associated with pan-HDAC inhibitors.  
 
Conclusion 
Our understanding of the biology of the GC lymphomas has increased dramatically 
with the introduction of NGS, and our ability to parallel clinical and molecular 
heterogeneity. There are signs that we are on the edge of a new precision era for GC 
lymphomas. Several new upfront prognostic strategies have been published for FL, 
and the seminal study by Reddy et al examining 1001 DLBCL patients has highlighted 
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the need for similar large scale, multi-institutional collaborative studies across all 
lymphomas, including FL. Furthermore, cfDNA assessment have raised the possibility 
of undertaking dynamic disease monitoring accounting for spatial and temporal 
heterogeneity and forecasting the trajectory of the tumor’s evolution in real-time. 
 
The identification of therapeutics targeted towards specific molecular lesions has 
also seen significant advances in GC lymphomas, including the observations of 
selective benefit for ibrutinib in ABC-DLBCL and tazemetostat in EZH2 mutant FL. The 
challenge now is to establish how best to combine upfront prognostication with 
dynamic monitoring, whilst retaining practicality, to ensure that patients receive the 
best possible treatment.  
 
Key points 
 Specific sub-groups of high-risk DLBCL patients within the COO entities are now 
recognized. 
 Notable advances made in identifying high-risk FL with the development of novel 
molecular prognostication tools. 
 Ibrutinib and tazemetostat are showing preferential benefit in specific 
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Figure 1. Actionable mutations in GC lymphomas. Diagram indicating key recurring 
and potentially targetable mutations. Highlighted therapeutics include ibrutinib for 
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